Monoclonal antibodies that inhibit the proteolytic activity of botulinum neurotoxin serotype/B

Toxins

Volumn 7, Issue 9, 2015, Pages 3405-3423

  Fan, Yongfeng ^a   Dong, Jianbo ^a   Lou, Jianlong ^a   Wen, Weihua ^a   Conrad, Fraser ^a   Geren, Isin N ^a,d   Garcia Rodriguez, Consuelo ^a   Smith, Theresa J ^b   Smith, Leonard A ^b   Ho, Mengfei ^c   Pires Alves, Melissa ^c   Wilson, Brenda A ^c   Marks, James D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

Author keywords

Alpha exosite; Botulinum antitoxin; Botulinum neurotoxin serotype B; Inhibitory antibodies

Indexed keywords

ALANINE; ANTITOXIN; BOTULINUM TOXIN B; EPITOPE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNAPTOBREVIN 2; BOTULINUM TOXIN A; SNARE PROTEIN;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CROSS REACTION; DISSOCIATION CONSTANT; DNA SEQUENCE; EPITOPE MAPPING; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; HUMAN; IC50; IMMUNIZATION; LIGHT CHAIN; MOUSE; MUTAGENESIS; NONHUMAN; PARALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; YEAST CELL; ANIMAL; IMMUNOLOGY; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTITOXINS; BOTULINUM TOXINS, TYPE A; EPITOPES; FEMALE; FLOW CYTOMETRY; INHIBITORY CONCENTRATION 50; MICE; PROTEIN CONFORMATION; PROTEOLYSIS; SINGLE-CHAIN ANTIBODIES; SNARE PROTEINS;

EID: 84940829280     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins7093405     Document Type: Article

References (41)

1. Gill, M.D. Bacterial toxins: A table of lethal amounts. Microbiol. Rev. 1982, 46, 86-94.
2. Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M.; et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285, 1059-1070.
3. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5, 898-902.
4. Chai, Q.; Arndt, J.W.; Dong, M.; Tepp, W.H.; Johnson, E.A.; Chapman, E.R.; Stevens, R.C. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 2006, 444, 1096-1100.
5. Dolly, J.O.; Black, J.; Williams, R.S.; Melling, J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 1984, 307, 457-460.
6. Dong, M.; Yeh, F.; Tepp, W.H.; Dean, C.; Johnson, E.A.; Janz, R.; Chapman, E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312, 592-596.
7. Montecucco, C. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem. Sci. 1986, 11, 315-317.
8. Rummel, A.; Mahrhold, S.; Bigalke, H.; Binz, T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 2004, 51, 631-643.
9. Simpson, L.L. Kinetic studies on the interaction between botulinum toxin type A and the chloinergic neuromuscular junction. J. Pharmacol. Expt. Ther. 1980, 212, 16-21.
10. Blaustein, R.O.; Germann, W.J.; Finkelstein, A.; DasGupta, B.R. The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers. FEBS Lett. 1987, 226, 115-120.
11. Fischer, A.; Montal, M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc. Natl. Acad. Sci. USA 2007, 104, 10447-10452.
12. Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; de Laureto, P.P.; DasGupta, B.R.; Montecucco, C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359, 832-835.
13. Chen, S.; Karalewitz, A.P.; Barbieri, J.T. Insights into the different catalytic activities of Clostridium neurotoxins. Biochemistry 2012, 51, 3941-3947.
14. Breidenbach, M.A.; Brunger, A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432, 925-929.
15. Arnon, S.S.; Schechter, R.; Maslanka, S.E.; Jewell, N.P.; Hatheway, C.L. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 2006, 354, 462-471.
16. Centers for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb. Mortal Wkly. Rep. 2010, 59, 299.
17. Nowakowski, A.; Wang, C.; Powers, D.B.; Amersdorfer, P.; Smith, T.J.; Montgomery, V.A.; Sheridan, R.; Blake, R.; Smith, L.A.; Marks, J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 2002, 99, 11346-11350.
18. Garcia-Rodriguez, C.; Levy, R.; Arndt, J.W.; Forsyth, C.M.; Razai, A.; Lou, J.; Geren, I.; Stevens, R.C.; Marks, J.D. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat. Biotechnol. 2007, 25, 107-116.
19. Lou, J.; Geren, I.; Garcia-Rodriguez, C.; Forsyth, C.M.; Wen, W.; Knopp, K.; Brown, J.; Smith, T.; Smith, L.A.; Marks, J.D. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng. Des. Sel. 2010, 23, 311-319.
20. Meng, Q.; Garcia-Rodriguez, C.; Manzanarez, G.; Silberg, M.A.; Conrad, F.; Bettencourt, J.; Pan, X.; Breece, T.; To, R.; Li, M.; et al. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal. Biochem. 2012, 430, 141-150.
21. Meng, Q.; Li, M.; Silberg, M.A.; Conrad, F.; Bettencourt, J.; To, R.; Huang, C.; Ma, J.; Meyer, K.; Shimizu, R.; et al. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal. Biochem. 2012, 421, 351-361.
22. Eubanks, L.M.; Hixon, M.S.; Jin, W.; Hong, S.; Clancy, C.M.; Tepp, W.H.; Baldwin, M.R.; Malizio, C.J.; Goodnough, M.C.; Barbieri, J.T. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. USA 2007, 104, 2602-2607.
23. Lebeda, F.J.; Cer, R.Z.; Mudunuri, U.; Stephens, R.; Singh, B.R.; Adler, M. The zinc-dependent protease activity of the botulinum neurotoxins. Toxins 2010, 2, 978-997.
24. Pang, Y.-P.; Davis, J.; Wang, S.; Park, J.G.; Nambiar, M.P.; Schmidt, J.J.; Millard, C.B. Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. PLoS ONE 2010, 5, e10129.
25. Kiris, E.; Burnett, J.C.; Kane, C.D.; Bavari, S. Recent advances in botulinum neurotoxin inhibitor development. Curr. Top Med. Chem. 2014, 14, 2044-2061.
26. Wilson, B.A.; Ho, M. Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism. Curr. Top Med. Chem. 2014, 14, 2081-2093.
27. Edupuganti, O.P.; Ovsepian, S.V.; Wang, J.; Zurawski, T.H.; Schmidt, J.J.; Smith, L.; Lawrence, G.W.; Dolly, J.O. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J. 2012, 279, 2555-2567.
28. Dong, J.; Thompson, A.A.; Fan, Y.; Lou, J.; Conrad, F.; Ho, M.; Pires-Alves, M.; Wilson, B.A.; Stevens, R.C.; Marks, J.D. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J. Mol. Biol. 2010, 397, 1106-1118.
29. Fan, Y.; Geren, I.; Dong, J.; Lou, J.; Wen, W.; Conrad, F.; Smith, T.J.; Smith, L.A.; Ho, M.; Pires-Alves, M.; Wilson, B.A.; Marks, J.D. Monoclonal antibodies targeting the alpha-exosite of botulinum neurotoxin serotype/A inhibit catalytic activity. PLoS ONE 2015, 10, e0135306.
30. Levy, R.; Forsyth, C.M.; LaPorte, S.L.; Geren, I.N.; Smith, L.A.; Marks, J.D. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J. Mol. Biol. 2007, 365, 196-210.
31. Swaminathan, S.; Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Mol. Biol. 2000, 7, 693-699.
32. Brunger, A.T.; Breidenbach, M.A.; Jin, R.; Fischer, A.; Santos, J.S.; Montal, M. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 2007, 3, e113.
33. Gao, J.; Sidhu, S.S.; Wells, J.A. Two-state selection of conformation-specific antibodies. Proc. Natl. Acad. Sci. USA 2009, 106, 3071-3076.
34. Eswaramoorthy, S.; Kumaran, D.; Keller, J.; Swaminathan, S. Role of metals in the biological activity of Clostridium botulinum neurotoxins. Biochemistry 2004, 43, 2209-2216.
35. Foran, P.; Shone, C.C.; Dolly, J.O. Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry 1994, 33, 15365-15374.
36. Olson, M.A.; Armendinger, T.L. Free-energy contributions to complex formation between botulinum neurotoxin type B and synaptobrevin fragment. Protein Eng. 2002, 15, 739-743.
37. Marks, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 1991, 222, 581-597.
38. Schier, R.; Bye, J.M.; Apell, G.; McCall, A.; Adams, G.P.; Malmqvist, M.; Weiner, L.M.; Marks, J.D. Isolation of high affinity monomeric human anti-c-erbB-2 single chain Fv using affinity driven selection. J. Mol. Biol. 1996, 255, 28-43.
39. Pires-Alves, M.; Ho, M.; Aberle, K.K.; Janda, K.D.; Wilson, B.A. Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. Toxicon 2009, 53, 392-399.
40. Ho, M.; Goh, C.H.; Brothers, M.C.; Wang, S.; Young, R.L.; Ou, Y.; Lui, J.N.; Kalafatis, M.; Lan, X.; Wolf, A.E.; et al. Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A. Protein Sci. 2012, 21, 318-326.
41. Razai, A.; Garcia-Rodriguez, C.; Lou, J.; Geren, I.N.; Forsyth, C.M.; Robles, Y.; Tsai, R.; Smith, T.J.; Smith, L.A.; Siegel, R.W.; et al. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J. Mol. Biol. 2005, 351, 158-169.